<International Circulation>: Could you talk about the main improvements in studies in the last 15 years and why we can see more precise results? Prof. Kjeldsen: We have better protocols, larger sample sizes, better statistical power and better follow-up. There is much less discontinuation in these mass clinical trials. We get better precision. Differences are not overwhelming, but we get statistical significance.
<International Circulation>: In ACCOMPLISH, the biggest difference was the drop in cardiovascular endpoint in patients taking the CCB ACE inhibitor? Prof. Kjeldsen:Yes, that’s right. There was a 20% reduction in the primary cardiovascular endpoint.
[1] [2] [3] 下一页
网友评论仅供其表达个人看法,并不表明国际循环同意其观点或证实其描述。 发表评论需登陆